PITTSBORO, NC--(Marketwire - March 18, 2008) - Biolex Therapeutics, Inc. announced today that researchers presented results at the 33rd Annual Scientific Meeting of the Society of Interventional Radiology (SIR) in Washington, D.C. demonstrating that the thrombolytic activity of the Company’s full-length recombinant plasmin (BLX-155) was superior to t-PA in a preclinical study. The preclinical results were presented by Imo Hoefer, MD, University Medical Center Utrecht, Holland, the leader of the research team conducting the study. BLX-155 is a direct-acting thrombolytic (clot dissolving) agent currently in preclinical development and is designed to break up blood clots in patients with diseases or conditions such as acute peripheral arterial disease, deep vein thrombosis and hemodialysis graft thrombosis, each of which currently lacks a safe and effective therapy.
